GSE158557
Expression profiling by RNA-seq of LNCaP cells expressing wild-type androgen receptor (AR-WT), AR-V7 splice variant or mutant AR-Q641X
The androgen receptor (AR) signaling remains the key therapeutic target in metastatic prostate cancer (PCa). However, development of castration resistant PCa is frequently observed and can be in part attributed to the expression of mutant AR variants, which lack the ligand binding domain and are thus constitutively active. These constitutive AR variants have been associated with castration resistance but also with tumor progression. However, little data is available regarding their transcriptional activities. In this study, we depicted the transcriptional landscapes of the two constitutive AR variants AR-Q641X and AR-V7 by whole transcriptome sequencing and Gene Set Enrichment Analysis. Overall design: Inducible expression of eGFP-AR-WT, eGFP-AR-Q641X, eGFP-AR-V7 or eGFP alone as a control was obtained from stable lentivirally transduced LNCaP cells. After 48 hours of growth /culture in hormone-depleted medium, cells were treated for 24 hours with 20ng/ml of doxycycline and 10nM of DHT or ethanol (EtOH) as vehicle. Total RNA was isolated and proceeded for RNA-seq.